60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
July 09, 2024 06:31 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.
60Degrees_logo_RGB_Logo.jpg
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
June 27, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
June 11, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives.
60Degrees_logo_RGB_Logo.jpg
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
May 30, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals to start the first clinical trial of tafenoquine for babesiosis at Tufts Medical Center. Enrollment begins June 13, 2024.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
May 20, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals funds a study at NC State to test for Babesia spp in chronic fatigue patients, aiming to link these infections to CFS symptoms.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
May 08, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma plans clinical trial of Tafenoquine for Babesiosis. Letter to Journal of Infectious Diseases outlines protocol. Enrollment starts summer.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
May 02, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
SXTP received FDA comments on tafenoquine-babesiosis trial protocol; no major changes are needed. Trial planning and execution to proceed as planned.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
February 08, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
Kristen Landon appointed Chief Commercial Officer at 60 Degrees Pharma leading ARAKODA® relaunch for malaria prevention and expanded tick-borne strategy.
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
January 22, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
Post-FDA meeting, 60 Degrees Pharma plans pivotal study of tafenoquine in hospitalized babesiosis patients, aiming to start in summer 2024. #biotech #SXTP
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024
December 26, 2023 07:59 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma has received IRB approval for a Phase IIA study evaluating tafenoquine's efficacy in treating hospitalized babesiosis patients, while the